Investment Rating - The report maintains a "Buy" rating for Shanghai Jahwa [4] Core Insights - The company's 2025 performance met expectations, with a significant recovery in operational quality, achieving a revenue of 6.317 billion yuan, a year-on-year increase of 11.25%, and a net profit of 268 million yuan, successfully turning a profit [1] - The gross margin improved to 62.6%, up by 5.0 percentage points year-on-year, indicating enhanced profitability [1] - The company aims for double-digit revenue growth in 2026, focusing on high-potential segments and expanding its portfolio of billion-yuan products [2][4] Financial Performance - In 2025, the personal care segment generated 2.419 billion yuan, a growth of 1.65%, while the beauty segment saw a remarkable increase of 53.70%, reaching 1.613 billion yuan [2] - The overseas business reported a revenue of 1.471 billion yuan, up by 3.9% [2] - The company’s online sales grew by 21.89%, with an improved gross margin of 3.28 percentage points year-on-year, while offline sales increased by 4.60% with a gross margin rise of 5.75 percentage points [3] Profit Forecast - The profit forecast for 2026-2028 has been adjusted, with expected net profits of 422 million yuan, 529 million yuan, and 649 million yuan respectively, translating to EPS of 0.63, 0.79, and 0.96 yuan per share [4]

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported a revenue of 6.317 billion yuan in 2025, representing a year-on-year growth of 11.2%. The net profit attributable to shareholders was 268 million yuan, marking a return to profitability. The net profit after deducting non-recurring items was 45 million yuan, also indicating a turnaround [2] - The growth in performance is primarily driven by the increase in core business revenue, improvement in gross margin, and higher investment income from fund investments and changes in fair value [2] Revenue Analysis - The company focused on core brands and successfully cultivated three billion-yuan products, significantly enhancing brand momentum. Notable products include: - Baicaojis Big White Mud with a GMV exceeding 200 million yuan - Yuze Dry Sensitive Cream, which saw growth surpassing the overall brand level after its relaunch - Liushen Mosquito Repellent Egg, which effectively captures outdoor economy trends and Gen Z consumption patterns, achieving an 8.2-hour long-lasting effect [3] - The company is enhancing brand building and product upgrades, with increased marketing efforts to strengthen brand recognition and drive high-quality growth [3] Online Business Growth - The company is actively promoting online business development, improving channel efficiency through tiered operations with key influencers and enhancing content quality. The core brand's Douyin self-broadcasting business has shown good growth [4] Profitability Analysis - The gross margin for Q4 2025 was 61.81%, an increase of 10.99 percentage points year-on-year. However, the net profit margin decreased to -10.16% due to an increase in R&D and marketing expenses [5] Investment Recommendations - The company is expected to continue benefiting from strategic adjustments and reforms, with successful product launches and enhanced brand momentum. The revenue forecasts for 2026-2028 are projected at 7.185 billion, 8.058 billion, and 8.864 billion yuan, respectively, with net profits of 339 million, 414 million, and 481 million yuan [6]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, highlighting strong performance from key players despite a recent market downturn [2][4]. Core Insights - The cosmetics and medical beauty sector has underperformed the market recently, with the Shenwan Beauty Care Index declining by 2.4% from March 20 to March 27, 2026, compared to a 1.7% decline in the Shenwan A Index [4][5]. - Notable companies such as Maogeping, Shangmei, and Linqingxuan reported significant revenue and profit growth for 2025, with Maogeping's revenue exceeding 5 billion yuan, marking a 30% increase, and Shangmei's revenue growing by 35.1% [4][10]. - Linqingxuan achieved a remarkable revenue growth of 102.5%, doubling its revenue from 12.1 billion yuan in 2024 to 24.5 billion yuan in 2025 [16]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown weaker performance compared to the overall market, with specific indices reflecting declines [4][5]. - The Shenwan Cosmetics Index fell by 2.9%, while the Shenwan Personal Care Index increased by 0.5%, indicating mixed performance within the sector [4][5]. Company Highlights - **Maogeping**: Achieved a revenue of 5.05 billion yuan in 2025, a 30% increase, with a net profit of 1.204 billion yuan, up 36.7% [10][11]. - **Shangmei**: Reported a revenue of 9.178 billion yuan, a 35.1% increase, and a net profit of 1.154 billion yuan, up 43.7% [11][12]. - **Linqingxuan**: Revenue reached 2.45 billion yuan, a 102.5% increase, with a net profit of 360 million yuan, up 92.9% [16][17]. - **Shanghai Jahwa**: Revenue of 6.317 billion yuan, an 11.25% increase, and a net profit of 268 million yuan, marking a return to profitability [20][21]. Market Trends - The report notes a strong performance in the e-commerce sector, with significant growth in online sales for major brands [27][30]. - The overall retail sales of cosmetics in China showed a growth of 4.5% in the first two months of 2026, indicating a resilient consumer demand [30][31]. Strategic Recommendations - The report recommends focusing on companies with strong brand matrices and high growth in GMV, such as Maogeping and Shangmei, while also highlighting potential in the mother and baby segment [4][10]. - It suggests monitoring companies with strong R&D capabilities and product pipelines in the medical beauty sector, such as Aimeike and Langzi [4][10].

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 31.08 CNY [5][19]. Core Insights - The company achieved a revenue growth of 11.25% in 2025, reaching 6.317 billion CNY, and turned a profit with a net profit of 268 million CNY [2][11]. - The beauty product category led the growth, and the online transformation showed significant results, indicating a positive outlook for continued revenue growth driven by major products [2][11]. - The company successfully cultivated three major products with over 100 million CNY in sales, showcasing the effectiveness of its focus on core strategies [11]. Financial Summary - Total revenue for 2025 is projected at 6.317 billion CNY, with a year-on-year increase of 11.2% [4]. - The net profit for 2025 is expected to be 268 million CNY, a significant turnaround from a loss of 833 million CNY in 2024 [4]. - Earnings per share (EPS) for 2025 is projected at 0.40 CNY, with expectations of gradual increases in subsequent years [4][12]. - The gross profit margin for 2025 is reported at 62.59%, an increase of 5 percentage points year-on-year [11]. Business Performance - The company’s personal care, beauty, innovation, and overseas businesses generated revenues of 2.419 billion CNY, 1.613 billion CNY, 0.811 billion CNY, and 1.471 billion CNY respectively in 2025, with beauty products showing a remarkable growth of 53.70% [11]. - Online sales increased by 21.89%, with domestic online channels growing by 36.9%, indicating improved operational efficiency and brand content capabilities [11]. - The company’s operating cash flow significantly improved, reaching 801 million CNY, a 193.3% increase year-on-year, reflecting enhanced operational quality [11].

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 31.08 CNY [5][19]. Core Insights - The company achieved a revenue growth of 11.25% in 2025, reaching 6.317 billion CNY, and turned a profit with a net profit of 268 million CNY [2][11]. - The beauty product category led the growth, and the online transformation showed significant results, indicating a positive outlook for continued revenue growth driven by major products [2][11]. - The company successfully cultivated three major products with over 100 million CNY in sales, showcasing the effectiveness of its focus on core strategies [11]. Financial Summary - Total revenue for 2025 is projected at 6.317 billion CNY, with a year-on-year increase of 11.25% [4]. - The net profit for 2025 is expected to be 268 million CNY, a significant recovery from a loss of 833 million CNY in 2024 [4]. - Earnings per share (EPS) for 2025 is estimated at 0.40 CNY, with projections of 0.71 CNY for 2026 and 0.90 CNY for 2027 [4][12]. - The company's gross margin improved to 62.59% in 2025, up by 5 percentage points year-on-year [11]. Business Performance - The company’s personal care, beauty, innovation, and overseas businesses generated revenues of 2.419 billion CNY, 1.613 billion CNY, 0.811 billion CNY, and 1.471 billion CNY respectively in 2025 [11]. - Online sales increased by 21.89%, with beauty products seeing a remarkable growth of 60.6% in online channels [11]. - The operational cash flow reached 801 million CNY in 2025, marking a substantial increase of 193.3% year-on-year [11].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company successfully turned a profit in 2025, with revenue of 6.317 billion yuan, a year-on-year increase of 11.25%, and a net profit attributable to shareholders of 268 million yuan, marking a turnaround from losses [4][6] - The gross margin improved significantly to 62.6%, up 5.0 percentage points year-on-year, and the net margin turned positive at 4.2% [6] - The company has cultivated three major products generating over 100 million yuan in sales, contributing to strong revenue growth [6] Financial Data and Profit Forecast - Revenue projections for 2026 are estimated at 7.124 billion yuan, with a year-on-year growth rate of 12.8% [5] - The net profit attributable to shareholders is forecasted to reach 430 million yuan in 2026, reflecting a growth rate of 60.7% compared to 2025 [5] - The company’s earnings per share (EPS) is expected to be 0.64 yuan in 2026, with a projected price-to-earnings (PE) ratio of 32 [5][6]

3月2 5日晚间，上海家化正式发布2 0 2 5年年度业绩报告。在国内化妆品行业整体增长放缓的大 背景下，公司全年实现营业收入6 3 . 2亿元，同比增长11 . 2%，归母净利润2 . 7亿元，较上年同 期 实 现 扭 亏 为 盈 ； 其 中 美 妆 业 务 全 渠 道 收 入 同 比 大 涨 5 3 . 7% ， 美 妆 业 务 线 上 渠 道 同 比 增 长 6 0 . 6%。 这份营收、利润、现金流全面向好的成绩单，距离林小海正式掌舵上海家化尚不满两年。而在 亮眼数字的背后，是这家百年企业历经一整年"卸包袱、寻出路"的深度改革后，迎来的基本面 实质性反转与品牌复兴新局。 对于这份成果，林小海给出了清晰的自评：" 我给自己打7 9分，给团队打8 0分。2 0 2 5年对比 2 0 2 4年有进步，但我们跟行业标杆还是有差距。 " 经历了2 0 2 4年的深度调整，2 0 2 5年的上海家化，不仅实现了营收与利润的双增长，更完成了 经营质量的全面优化，企业自我造血能力得到显著修复。 按照业务板块划分，上海家化四大业务板块毛利润均实现同比上升，整体营收效率得到明显改 善，各板块呈现差异化增长格局： 1 .核 ...

Investment Rating - The report maintains a "Buy" rating for Shanghai Jahwa (600315) [1] Core Insights - In 2025, the company turned a profit with significant growth in the beauty segment, indicating a marked improvement in operational quality [7] - The company achieved a revenue of 6.32 billion yuan in 2025, a year-on-year increase of 11.25%, and a net profit of 267.58 million yuan, marking a turnaround from losses [7] - The beauty segment saw a remarkable growth of 53.7%, with online revenue increasing by 21.9% [7] Financial Summary - Revenue Forecast: - 2024A: 5.679 billion yuan - 2025A: 6.317 billion yuan - 2026E: 7.195 billion yuan - 2027E: 8.044 billion yuan - 2028E: 8.919 billion yuan - Net Profit Forecast: - 2024A: -833.09 million yuan - 2025A: 267.58 million yuan - 2026E: 364.39 million yuan - 2027E: 445.84 million yuan - 2028E: 534.45 million yuan - EPS (Latest Diluted): - 2024A: -1.24 yuan - 2025A: 0.40 yuan - 2026E: 0.54 yuan - 2027E: 0.66 yuan - 2028E: 0.80 yuan - P/E Ratios: - 2024A: -16.86 - 2025A: 52.48 - 2026E: 38.54 - 2027E: 31.50 - 2028E: 26.28 [1][8] Operational Highlights - The company successfully launched three major products generating over 100 million yuan in sales each, indicating a robust product pipeline [7] - The overall gross margin improved to 62.6% in 2025, up by 5.0 percentage points year-on-year, driven by the increased share of beauty products and reduced raw material costs [7] - The company reported a significant improvement in cash flow, with net cash flow from operating activities reaching 800 million yuan, a year-on-year increase of 193% [7]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, suggesting a focus on pre-festival promotions as a key opportunity for growth [3][10]. Core Insights - The cosmetics and medical beauty sector has underperformed the market recently, with the Shenwan Beauty Care Index declining by 3.8% from January 23 to January 30, 2026, which is worse than the overall market performance [4][5]. - Recent earnings forecasts from companies like Shanghai Jahwa, Ruya Chen, and Huaxi Biological indicate a recovery in profitability, highlighting the sector's high growth potential [10][11]. - The upcoming Spring Festival is expected to drive significant promotional activities, particularly on platforms like Tmall and Douyin, which could enhance sales for domestic brands [10][11]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown a decline, with the Shenwan Cosmetics Index down 3.6% and the Shenwan Personal Care Index down 4.6%, both underperforming the Shenwan A Index [4][5]. - The top-performing stocks in the sector include Qingdao Kingway (+7.2%) and Beijia Clean (+0.1%), while the worst performers include Lafang Jiahua (-18.7%) and Shanghai Jahwa (-10.9%) [6]. Earnings Forecasts - Companies like Ruya Chen expect a net profit of 176 to 200 million yuan for 2025, representing a year-on-year increase of 66.61% to 89.33% [4]. - Shanghai Jahwa anticipates a turnaround with a projected net profit of 240 to 290 million yuan for 2025, while Huaxi Biological expects a net profit of 270 to 320 million yuan, reflecting a growth of 54.93% to 83.63% [4][10]. Market Trends - The retail sales of cosmetics in 2025 are projected to grow by 5.1%, with a notable increase in Q4 driven by promotional events like Double Eleven [11][19]. - The report highlights the strong performance of domestic brands, with significant growth in online sales channels, particularly on Douyin [12][29]. Investment Recommendations - Key recommendations include focusing on brands with strong growth in GMV such as Mao Ge Ping, Shangmei Co., and Shanghai Jahwa, as well as companies in the medical beauty sector like Aimeike and Langzi Co. [14][30]. - The report also suggests monitoring e-commerce operations and self-owned brands like Ruya Chen and Qingmu Technology for potential high growth [14][30].

Core Viewpoint - Shanghai Jahwa expects to achieve a net profit of between 240 million and 290 million yuan in 2025, marking a turnaround from losses to profits due to growth in core business, improved gross margins, and increased non-recurring income [1] Group 1 - In 2025, Shanghai Jahwa's strategic focus will be on core brands, brand building, online presence, and operational efficiency, which will drive the company's performance [1] - The company has successfully launched several billion-yuan products, enhancing the competitiveness of its core brands and accelerating brand momentum [1] - The CEO emphasized that in the online era, flagship products are crucial for establishing brand recognition and building a product matrix for long-term development [1] Group 2 - In the fourth quarter of 2025, Shanghai Jahwa established a Billion-Yuan Product Club to leverage brand resources and operational experience to create a matrix of blockbuster products [2] - The club aims to expand the billion-yuan product matrix through a complete incubation process to drive company growth [2]